知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

104 条记录 (耗时 0.04 秒)

    Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses Thereof
    81.
    发明申请
    Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses Thereof 审中-公开

    公开(公告)号：US20190127480A1

    公开(公告)日：2019-05-02

    申请号：US16205917

    申请日：2018-11-30

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Jessica R. Kirshner ,  Alison Crawford ,  Gavin Thurston ,  Eric Smith ,  Lauric Harber ,  Drew Dudgeon ,  Ashique Rafique

    IPC分类号： C07K16/30 ,  C07K16/28 ,  A61P35/00

    摘要： The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

    Methods and Antibody Compositions for Tumor Treatment
    85.
    发明申请
    Methods and Antibody Compositions for Tumor Treatment 审中-公开
    用于肿瘤治疗的方法和抗体组合物

    公开(公告)号：US20150266966A1

    公开(公告)日：2015-09-24

    申请号：US14661334

    申请日：2015-03-18

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Eric Smith ,  Samuel Davis ,  Bindu Varghese ,  Jessica R. Kirshner ,  Gavin Thurston

    IPC分类号： C07K16/28

    摘要： The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

    摘要翻译： 本发明提供了结合CD3和肿瘤抗原的双特异性抗体及其使用方法。 根据某些实施方案，本发明的双特异性抗体表现出降低的效应子功能并且具有关于Fcγ受体的独特结合特征。 双特异性抗体被工程化以有效诱导T细胞介导的杀伤肿瘤细胞。 根据某些实施方案，本发明提供双特异性抗原结合分子，其包含特异性结合人CD3的第一抗原结合结构域，特异性结合人CD20的第二抗原结合分子和与特异性结合Fcγ受体的Fc结构域 绑定模式。 在某些实施方案中，本发明的双特异性抗原结合分子能够抑制表达CD20的B细胞或黑素瘤肿瘤的生长。 本发明的双特异性抗体可用于治疗各种癌症以及其它与CD20相关的疾病和病症。